patritumab
daiichi sankyo
['patritumab']
 ian krop presents impressive phase 1/2 results with the her3 adc patritumab deruxtecan. response seen across her3 expression, her3 expr varied over time (both up and down) but didn t correlate to orr. one grade 5 ild. 